- Home
- DTIL vs RNXT Comparison
DTIL vs RNXT Comparison
Compare DTIL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- RNXT
- Stock Information
- Founded
- DTIL 2006
- RNXT 2012
- Country
- DTIL United States
- RNXT United States
- Employees
- DTIL N/A
- RNXT N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- RNXT Health Care
- Exchange
- DTIL Nasdaq
- RNXT Nasdaq
- Market Cap
- DTIL 51.6M
- RNXT 44.6M
- IPO Year
- DTIL 2019
- RNXT 2021
- Fundamental
- Price
- DTIL $4.49
- RNXT $1.30
- Analyst Decision
- DTIL Strong Buy
- RNXT Strong Buy
- Analyst Count
- DTIL 2
- RNXT 2
- Target Price
- DTIL $47.00
- RNXT $7.25
- AVG Volume (30 Days)
- DTIL 546.0K
- RNXT 135.9K
- Earning Date
- DTIL 07-31-2025
- RNXT 08-12-2025
- Dividend Yield
- DTIL N/A
- RNXT N/A
- EPS Growth
- DTIL N/A
- RNXT N/A
- EPS
- DTIL N/A
- RNXT N/A
- Revenue
- DTIL $51,141,000.00
- RNXT $240,000.00
- Revenue This Year
- DTIL N/A
- RNXT $3,104.65
- Revenue Next Year
- DTIL $30.20
- RNXT $301.89
- P/E Ratio
- DTIL N/A
- RNXT N/A
- Revenue Growth
- DTIL N/A
- RNXT N/A
- 52 Week Low
- DTIL $3.61
- RNXT $0.75
- 52 Week High
- DTIL $11.09
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- RNXT 53.41
- Support Level
- DTIL $4.08
- RNXT $1.29
- Resistance Level
- DTIL $4.38
- RNXT $1.38
- Average True Range (ATR)
- DTIL 0.28
- RNXT 0.07
- MACD
- DTIL 0.05
- RNXT -0.01
- Stochastic Oscillator
- DTIL 85.26
- RNXT 48.39
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.